The X+ chronic granulomatous disease as a fabulous model to study the NADPH oxidase complex activation;La granulomatose septique chronique X+: Un fabuleux modèle d'étude de l'activation du complexe NADPH oxydase

Medecine/Sciences

Volumn 23, Issue 5, 2007, Pages 526-532

  Stasia, Marie José ^a  

^a GREPI   (France)

Author keywords

[No Author keywords available]

Indexed keywords

CYTOCHROME B558; GLYCOPROTEIN GP 91; PROTEIN P22; PROTEIN P40; PROTEIN P47; PROTEIN P67; RAC2 PROTEIN; RAP1 PROTEIN; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE OXIDASE; SUPEROXIDE;

BACTERIAL INFECTION; CHRONIC GRANULOMATOUS DISEASE; ENZYME ACTIVATION; ENZYME ACTIVITY; GENE MUTATION; HUMAN; MOLECULAR BIOLOGY; MYCOSIS; PATHOGENESIS; PHAGOCYTE; RECURRENT DISEASE; REVIEW;

BACTERIA (MICROORGANISMS);

EID: 34249707835     PISSN: 07670974     EISSN: None     Source Type: Journal    
DOI: 10.1051/medsci/2007235526     Document Type: Review

References (30)

1. Winkelsteinw JA, Marino MC, Johnston RB, et al. Chronic granulomatous disease. Report on a national registry of 368 patients. Medicine (Baltimore) 2000 ; 79 : 155-69.
2. Guichard C, Pedruzzi E, Fay M, et al. The Nox/Duox family of ROS-generating NADPHoxidases. Med Sci (Paris) 2006 ; 22 : 953-9.
3. Berthier S, Paclet MH, Lerouge S, et al. Changing the conformation state of cytochrome b558 initiates NADPH oxidase activation: MRP8/MRP14 regulation J Biol Chem 2003 ; 278 : 25499-508.
4. + flux. Nature 2002 ; 416 : 291-7.
5. Wallach TM, Segal AW. Analysis of glycosylation sites on gp91phox, the flavocytochrome of the NADPH oxidase, by site-directed mutagenesis and translation in vitro. Biochem J 1997 ; 321 : 583-5.
6. Segal AW, West I, Wientjes F, et al. Cytochrome b245 is a flavocytochrome containing FAD and NADPH-binding site of the microbicidal oxidase of phagocytes Biochem J 1992 ; 284 : 781-8.
7. + channel is contained within the multi-membrane-spanning N-terminal region of gp91-phox. Biochem J 1997 ; 325 : 701-5.
8. DeCoursey TE, Cherny VV, Morgan D, Katz BZ, Dinauer MC. The gp91phox component of NADPH oxidase is not the voltage-gated proton channel in phagocytes, but it helps. J Biol Chem 2001 ; 276 : 36063-6.
9. Segal BH, Leto TL, Gallin JI, Malech HL, Holland SM. Genetic, biochemical, and clinical features of chronic granulomatous disease. Medicine (Baltimore) 2000 ; 79 : 170-200.
10. Roos D, De Boer M, Kuribayashi F, et al. Mutations in the X-linked and autosomal recessive forms of chronic granulomatous disease. Blood 1996 ; 87: 1663-81.
11. Stasia MJ, Bordigoni P, Floret D, et al. Characterization of six novel mutations in the CYBB gene leading to different sub-types of X-linked chronic granulomatous disease. Hum Genet 2005 ; 116 : 72-82.
12. Stasia MJ, Brion JP, Boutonnat J, Morel F. Severe clinical forms of cytochrome b-negative chronic granulomatous disease (X91-) in 3 brothers with a point mutation in the promoter region of CYBB. J Infect Dis 2003 ; 188 : 1593-604.
13. Heyworth PG, Curnutte JT, Rae J, et al. Hematologically important mutations: X-linked chronic granulomatous disease (second update). Blood Cells Mol Dis 2001 ; 27 : 16-26.
14. Heyworth PG, Cross AR, Curnutte JT. Chronic granulomatous disease. Curr Opin Immunol 2003 ; 15 : 578-84.
15. Cross AR, Heyworth PG, Rae J, Curnutte JT. A variant X-linked chronic granulomatous disease patient (X91+) with partially functional cytochrome b. J Biol Chem 1995 ; 270 : 8194-8200.
16. +) case with a double missense mutation in the gp91-phox-cytosolique C-terminal tail. Biochem Biophys Acta 2002 ; 1586 : 316-30.
17. 558 of the human NADPH oxidase leading to defective translocation of the cytosolic proteins p47-phox and p67-phox. J Clin Invest 1994 ; 93 : 2120-6.
18. Leusen JH, Meischl C, Eppink MH, et al. Four novel mutations in the gene encoding gp91-phox of human NADPH oxidase : consequences for oxidase assembly. Blood 2000 ; 95 : 666-73.
19. Dinauer MC, Curnutte JT, Rosen H, Orkin SH. A missense mutation in the neutrophil cytochrome b heavy chain in cytochrome-positive X-linked chronic granulomatous disease. J Clin Invest 1989 ; 84 : 2012-6.
20. Tucker KA, Lilly MB, Heck L, Rado TA. Characterization of a new human diploid myeloid leukaemia cell line (PLB-985). Blood 1987 ; 70 : 372-8.
21. Zhen L, King AA, Xiao Y, et al. Gene targeting of X chromosome-linked chronic granulomatous disease locus in a human myeloid leukemia cell line and rescue by expression of recombinant gp91phox. Proc Natl Acad Sci USA 1993 ; 90 : 9832-6.
22. Schapiro BL, Newburger PE, Klempner MS, Dinauer MC. Chronic granulomatous disease presenting in a 69-year-old man. N Engl J Med 1991 ; 325 : 1786-90.
23. Yu L, Cross AR, Zhen L, Dinauer MC. Functional analysis of NADPH oxidase in granulocytic cells expressing a delta488-497 gp91(phox) deletion mutant. Blood 1999 ; 94 : 2497-504.
24. Lambeth JD. NOX enzymes and the biology of reactive oxygen. Nat Rev Immunol 2004 ; 4 : 181-9.
25. Taylor WR, Jones DT, Segal AW. A structural model for the nucleotide binding domains of the flavocytochrome b-245 beta-chain. Protein Sci 1993 ; 2 : 1675-85.
26. Li, XJ, Grunwald D, Mathieu J, Morel F, Stasia MJ. Crucial role of two potential cytosolic regions of Nox2, 191TSSTKTIRRS200 and 484DESQANHFAVHHDEEKD500, on NADPH oxidase activation. J Biol Chem 2005 ; 280 : 14962-73.
27. 558 during phagocytic NADPH oxidase assembly. J Leukoc Biol 2007 ; 81 : 238-49.
28. Shatwell KP, Dancis A, Cross AR, Klausner RD, Segal AW. The FRE1 ferric reductase of Saccharomyces cerevisiae is a cytochrome b similar to that of NADPH oxidase. J Biol Chem 1996 ; 271 : 14240-4.
29. Karplus PA, Daniels MJ, Herriott JR. Atomic structure of ferredoxin-NADP+ reductase : prototype for a structurally novel flavoenzyme family. Science 1991 ; 251 : 60-6.
30. 558-positive chronic granulomatous disease by means of transgenic PLB-985 cells. Hum Genet 2004 ; 115 : 418-27.